Asian countries, and is the second greatest cause of cancer deaths in the world [1, 2] . A number of studies have established that Helicobacter pylori infection is a feasible risk factor for gastric cancer through the development of gastric atrophy or subsequent precancerous lesions [3, 4] . Severe gastric atrophy and corpuspredominant gastritis, as well as intestinal metaplasia, are generally recognized as predominant predispositions to gastric cancer [5] . Host proinfl ammatory genetic factors, in combination with bacterial virulence factors such as CagA, have been shown to determine the severity of gastric damage and the subsequent clinical outcome of H. pylori infection [6, 7] .
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Toll-like receptors (TLRs) are type-I transmembrane proteins with extracellular leucine-rich repeat (LRR) motifs and an intracellular Toll/interleukin-1 receptor (TIR) domain [8] . Toll, the founding member of the TLR family, was initially implicated in the establishment of dorsal-ventral patterning in the early development of the Drosophila embryo. Mammalian TLRs have essential roles in the direct recognition of infectious agents, leading to the activation of both innate and adaptive immune responses via nuclear factor-kappa B (NF-κB) signaling pathways. Ten different human TLRs have been identifi ed [9] . Each TLR recognizes specifi c pathogen-associated molecular patterns (PAMPs), including the recognition of lipoproteins, lipoteichoic acid, and zymosan by TLR2; double-stranded (ds) RNA by TLR3; lipopolysaccharide (LPS) by TLR4; fl agellin by TLR5; single-stranded (ss) RNA by TLR7/8; and C-phosphate-G (CpG) DNA by TLR9 [10] . Among them, TLR2 is reportedly expressed in H. pylori-infected gastric epithelial cells, and H. pylori induces NF-κB activation and subsequent chemokine expression by gastric epithelial cells through TLR2. Biological examinations have revealed that the transfection of cells with TLR2 induced augmented expression of interleukin (IL)-8, macrophage infl ammatory protein (MIP)-3α, and growth-regulated oncogene (GRO)-α [11] . Thus, TLR2
Introduction
Gastric cancer accounts for the greatest proportion of gastrointestinal tract cancers in Japan and other East is assumed to play essential roles in the host gastric mucosal defense against H. pylori infection.
Recently, an association between the TLR2 -196 to 174 del polymorphism, which has been biologically shown to infl uence the promoter activity of TLR2, and the risk of gastric cancer was reported [12] . Accordingly, we conducted a case-control study, with our gastric cancer casecontrol dataset, to verify this reported association between the TLR2 -196 to 174 del polymorphism and gastric cancer risk.
Subjects and methods

Subjects
The study subjects were participants in the Hospitalbased Epidemiologic Research Program at Aichi Cancer Center (HERPACC) study, in which fi rst-visit outpatients were consecutively invited to provide lifestyle data and blood samples after giving their informed consent [13] . Among the participants who visited Aichi Cancer Center Hospital from the years 2001 to 2005, 583 patients diagnosed with gastric cancer (cases) and 1636 age-and sex-frequency-matched cancer-free outpatients (controls) were recruited. This gastric cancer case-control dataset is the same as the one previously described [14, 15] . Informed consent was obtained from all the subjects and the study protocol was approved by the Ethics Committees of Aichi Cancer Center and Nagoya University Graduate School of Medicine.
Laboratory tests
The serum samples of the participants were immediately stored at −20°C until analysis. Anti-H. pylori IgG antibody was measured with a direct enzyme-linked immunosorbent assay (ELISA) kit, E Plate "Eiken" H. pylori Antibody (Eiken Kagaku, Tokyo, Japan). According to the instructions for this kit, a fi nding of 10.0 units or higher was regarded as seropositive. Serum pepsinogens (PGs) were measured by chemiluminescence enzyme immunoassay (CLEIA). Gastric mucosal atrophy was grouped into categories of "none" (PG I > 70 ng/ml or PG I/PG II > 3), "mild" (PG I ≤ 70 ng/ml and PG I/PG II ≤ 3, excluding "severe" cases), or "severe" (PG I ≤ 30 ng/ml and PG I/PG II ≤ 2). Because it was planned to use the serum samples of the gastric cancer cases for a study with higher priority, the H. pylori antibody and PG levels of the cases were not measured.
Genotyping
DNA was extracted from the buffy coat with a DNeasy mini-kit (QIAGEN, Tokyo, Japan). The TLR2 -196 to -174del polymorphism was genotyped with a polymerase chain reaction (PCR). The primers were: F1, CAC GGA GGC AGC GAG AAA; R1, CTG GGC CGT GCA AAG AAG, as described previously [12] . Amplifi cation conditions were 10 min of initial denaturation at 95°C, followed by 35 cycles of 1 min at 95°C, 1 min at 62°C, and 1 min at 72°C, then a 5-min fi nal extension at 72°C. The amplifi ed DNA was visualized on a 2% agarose gel with ethidium bromide staining. The amplifi ed DNA was 286 bp for the ins allele and 263 bp for the del allele. We found a new form of TLR2 variant allele with a longer insertion than that of the common ins allele in one control subject, who was excluded from the analyses in this study because the function of this newly found allele is still unknown. Representative gel for genotyping is shown in Fig. 1 .
Statistical analysis
Differences in percentages were examined with Fisher's exact test. The 95% confi dence intervals (CIs) for percentages were calculated based on binomial distributions. Logistic regression analysis was performed for estimating odds ratios (ORs) and 95% CIs. Age adjustment in 
Results
Characteristics of the subjects and allele frequency of the TLR2 polymorphism
The characteristics of the subjects are summarized in Table 1 . The mean age ± SD was 58.7 ± 10.6 years for the controls and 58.8 ± 10.5 years for the cases. The percentages of females were 26.5% in the controls and 26.4% in the cases. About three-quarters of the controls were infected with H. pylori, while about one-third of the controls had gastric atrophy. The genotype frequency of the TLR2 polymorphism among the controls was 44.1% for ins/ins, 44.6% for ins/del, and 11.2% for del/del, which was in Hardy-Weinberg equilibrium (χ 2 = 0.001; P = 0.9796). The allele frequency was 66.4% for the ins allele and 33.6% for the del allele. Among the cases the genotype frequency was 41.7% for ins/ins, 45.8% for ins/del, and 12.5% for del/del. The allele frequency was 64.6% for the ins allele and 35.4% for the del allele.
TLR2 polymorphism, H. pylori seropositivity, gastric atrophy, and gastric cancer H. pylori seropositivity was not associated with sex, but increased with age. There was no signifi cant association between the TLR2 polymorphism and H. pylori seropositivity, although the OR of the del/del genotype was 0.90 (95% CI: 0.64-1.26) and that of the ins/del + del/ del genotype was 0.92 relative to the ins/ins genotype ( Table 2) .
There were 937 H. pylori-seropositive subjects, of whom 494 (52.7%) subjects had atrophy. On the other hand, there were 45 (6.4%) subjects with atrophy among the 699 seronegative subjects. The difference in the prevalence was statistically signifi cant (P < 0.001). The genotype distribution according to seropositivity and atrophy is shown in Table 3 .
The age-and sex- (Table 4) .
To investigate how this polymorphism of TLR2 contributes to gastric carcinogenesis from gastric atrophy, we next compared the genotype frequency between gastric atrophy subjects and gastric cancer cases. The age-and sex-adjusted ORs of gastric cancer were 1.13 (95% CI: 0.88-1.46) for ins/del, 1.17 (95% CI: 0.79-1.73) for del/del, and 1.14 (95% CI: 0.89-1.45) for ins/del + del/ del, relative to the ins/ins genotype, and none of these were statistically signifi cant (Table 5) . GA (−), subjects with no gastric atrophy; GA (+), subjects with gastric atrophy (PG I ≤ 70 ng/ml and PG I/PG II ≤ 3); GA (++), subjects with severe gastric atrophy (PG I ≤ 30 ng/ml and PG I/PG II ≤ 2) 
Discussion
In this study, the previously reported association of the TLR2 -196 to -174del polymorphism with the risk of gastric cancer was not reproduced. Possible explanations for the discrepancies observed between the results of our study and the study reported in [17] can be speculated as follows. One explanation is that the signifi cant increase in risk of gastric cancer reported for those with the TLR2-196 to -174 del/del genotype in the study reported in [17] could have been a type-1 error, due to the relatively small number of study subjects with the TLR2-196 to -174 del/del genotype in that study. Another explanation is that the lack of association observed in the present study could be attributable to the heterogeneity of gastric cancer locations in the case subjects; the subsite distributions in the gastric cancer cases (cardia, fundus, body, pylorus, or antrum) were not specifi ed in this study. However, considering that more than 80% of gastric cancers in Japan are noncardia gastric cancers (NCGCs), as described previously [16] , it would seem that the infl uence of this heterogeneity of gastric cancer subsites would not have been so large as to modulate the effect of this TLR2 polymorphism on the risk of gastric cancer. The unique point of the present study compared to other studies is that that we investigated the association of the TLR2 polymorphism with the risks of two steps leading to gastric cancer: H. pylori infection, gastric atrophy, and gastric cancer itself. Although this study failed to detect a statistically signifi cant association, this type of analysis should be conducted in future studies so that we can clarify in which step the investigated factor has effects on H. pylori-related gastric carcinogenesis. In addition, we also conducted analyses in subjects older than 60 years of age to verify the reported association between the TLR2 -196 to -174del polymorphism and the severity of intestinal metaplasia in those aged 60 years or more [17] , and no signifi cant associations were revealed (data not shown). The discrepancy observed between the present study and the previous report [17] could be mainly attributable to the lack of information on the presence of intestinal metaplasia in our study subjects. Further examinations of the association between this TLR2 polymorphism and the risk of intestinal metaplasia are also required.
TLRs have been shown to have the ability to recognize pathogens or pathogen-derived products and to initiate signals leading to the activation of innate immunity responses [18, 19] . In H. pylori infection, it is generally accepted that TLRs are involved in the initial recognition of this bacterium. However, it is still controversial whether H. pylori's LPS is recognized by TLR4 or TLR2. Some studies have provided strong evidence that TLR4 is expressed by gastric epithelial cells and the LPS of H. pylori is involved in the signaling pathways leading to the production of proinfl ammatory cytokines [20] [21] [22] ; however, some other studies have shown contradictory results; e.g., the study by Smith et al. [11] revealed that H. pylori LPS is a TLR2 ligand and not a TLR4 ligand. Later, it was also shown that TLR4 signaling initiated by H. pylori LPS induced TLR2 expression in gastric epithelial cells [23] . For the association between polymorphisms in the TLR genes and the risk of gastric cancer, associations between polymorphisms in the TLR4 gene and the risk of gastric cancer are well documented, although there exists only one report regarding the association between polymorphisms in the TLR2 gene and the risk of gastric cancer [12] . Considering the important roles of TLRs in H. pylori infection, further investigations into the associations of genetic polymorphisms in TLR genes with the risk of H. pylori infection, gastric atrophy, or gastric cancer, along with further in vivo studies of the roles of TLRs in H. pylori-induced gastric carcinogenesis are expected to elucidate the precise molecular mechanisms involved in human H. pylori-induced gastric carcinogenesis, and it is hoped that such studies will lead to effective methods of individualizing the prevention of H. pylori-related gastric cancer.
Four polymorphisms in the TLR2 gene have been reported to date: -196 to -174del, -191G/A, 597T/C, and 1350T/C [24] . Although the functional roles of the polymorphisms other than the TLR2 -196 to -174del polymorphism have not yet been clarifi ed, it would also be intriguing to examine the associations between these polymorphisms and the risk of gastric cancer.
The present study has several limitations. Although the H. pylori status of the control subjects was examined with a serology test, we did not check the CagA status. As reported in Japan, nearly 100% of H. pylori strains possess a functional cag pathogenicity island (cagPAI), which encodes and produces the CagA protein [25] . A previous study also confi rmed that almost all strains isolated from the subjects in our Japanese dataset were East Asian cagA-positive strains [26, 27] , indicating that the H. pylori strains in our present study subjects also possessed CagA. Another limitation is related to the diagnosis of atrophic gastritis. This was done entirely on the basis of serum pepsinogen (PG) levels and not through histological assessment. However, the PG method is well established as a surrogate marker of atrophic gastritis [28] [29] [30] . The validated criterion is PG I 70 ng/ml or less and a PG I/PG II ratio of 3.0 or less, and that for severe atrophic gastritis is PG I 30 ng/ml or less and a PG I/PG II ratio of 2.0 or less, both of which are assumed to be reliable because they are widely used in practice in Japan [31, 32] . H. pylori seropositivity and PG levels were not examined in the gastric cancer cases in this study, based on the assumption that most of the gastric cancer cases would be H. pylori-positive with atrophic gastritis [33, 34] . Considering that the intestinal type of gastric cancer, the predominant type of gastric cancer in Japan, arises from gastric atrophy caused by H. pylori infection, and diffuse-type gastric cancer occurs regardless of gastric atrophy [35, 36] , and noncardia gastric cancer is associated with H. pylori infection and gastric atrophy while cardia gastric cancer is not [37] , it would be intriguing to perform subgroup analysis according to these two histological types or tumor locations. These analyses might help to unveil the association of this TLR2 polymorphism with the steps of gastric carcinogenesis more clearly. However, we could not perform these analyses because of the un availability of histological data and data about tumor location.
The del allele frequency of the TLR2 -196 to -174del polymorphism in our control subjects was 33.6% (1098 del alleles/3272 alleles), which was similar to the del allele frequency in the controls in a previous report in Japan; 31.3% (117 del alleles/374 alleles) [24] , and slightly higher than that in the report by Tahara et al. [12] ; 27.7% (81 del alleles/292 alleles). This discrepancy in the del allele frequency among the controls might partly explain the contradictory results of our study and the study reported by Tahara et al. [12] . The del allele frequency in people of other ethnicities has not yet been reported even in the Database of Single Nucleotide Polymorphisms (dbSNP) and the International HapMap Project (HapMap) databases [38, 39] . In the present study we found a new long insertion allele, which, as far as we know, is reported here for the fi rst time. The function of this new long insertion allele is not yet known, and this warrants further biological and epidemiological investigations. The genotype distribution among our controls was not signifi cantly different from Hardy-Weinberg equilibrium (P = 0.9796), suggesting that no selective mechanisms existed among the control subjects.
In this study, 699 H. pylori seropositive control subjects and 937 H. pylori seronegative control subjects were compared for an estimation of the risk of H. pylori seropositivity; 443 subjects without gastric atrophy and 494 subjects with gastric atrophy among H. pylori seropositive control subjects were compared for the risk estimation of gastric atrophy, and 539 control subjects with gastric atrophy and 583 subjects with gastric cancer were compared for the risk estimation of gastric cancer. The statistical power for a sample with 400 cases and 400 controls was more than 65% for an OR of 1.5 or 0.67 with a two-sided α-error of 0.05, when a genotype frequency among the controls was between 30% and 70%, and the statistical power was more than 50% when a genotype frequency among the controls was between 20% and 80%, making the statistical power for the present sample enough to detect a defi nite association.
In summary, this study has revealed that the TLR2 -196 to -174del polymorphism is not signifi cantly associated with the risk of H. pylori infection, atrophic gastritis, or gastric cancer in Japanese, suggesting that the infl uence of this TLR2 polymorphism on H. pylori-induced gastric carcinogenesis is limited in Japanese people. However, considering the important roles of TLR2 in H. pylori infection, it would be intriguing to investigate the roles of TLR2 polymorphisms in H. pylori-induced gastric carcinogenesis. Further examinations with larger numbers of study subjects are expected to verify our fi ndings.
